FDA needs better data to treat women and chronic pain

© Getty Images
Recent hopes of a new treatment for a common chronic pain condition, osteoarthritis (OA), were dashed when a much-anticipated novel OA pain drug was not approved by the FDA’s expert panel because of safety concerns. Currently, there is no targeted therapy for this condition and most patients manage it by using either NSAIDS or opioids and joint replacement surgery when worsening of the joint occurs.
OA, a degenerative chronic pain condition, disproportionately affects women — and its symptoms are more severe in women. Research over the years has well documented these sex and gender differences with regard to prevalence, incidence and severity of this disease in knee and hips. This includes women being more likely to undergo knee or hip arthroplasty compared to men.

Related Keywords

,Health Care ,Women ,Arthritis ,Health ,Fda ,Drug Prescriptions ,Clinical Trials ,ஆரோக்கியம் பராமரிப்பு ,பெண்கள் ,கீல்வாதம் ,ஆரோக்கியம் ,ஃப்ட ,மருந்து ப்ரிஸ்க்ரிப்ஶந்ஸ் ,மருத்துவ சோதனைகள் ,